ID: ALA3403182

Max Phase: Preclinical

Molecular Formula: C15H13N3OS

Molecular Weight: 283.36

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CN(Cc1ccccc1)c1nc(=O)c2cccnc2s1

Standard InChI:  InChI=1S/C15H13N3OS/c1-18(10-11-6-3-2-4-7-11)15-17-13(19)12-8-5-9-16-14(12)20-15/h2-9H,10H2,1H3

Standard InChI Key:  WGLAKBYDFKQWPL-UHFFFAOYSA-N

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 283.36Molecular Weight (Monoisotopic): 283.0779AlogP: 2.69#Rotatable Bonds: 3
Polar Surface Area: 46.09Molecular Species: NEUTRALHBA: 5HBD: 0
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: CX LogP: 2.85CX LogD: 2.85
Aromatic Rings: 3Heavy Atoms: 20QED Weighted: 0.74Np Likeness Score: -1.63

References

1. Inami H, Shishikura J, Yasunaga T, Ohno K, Yamashita H, Kato K, Sakamoto S..  (2015)  Synthesis, structure-activity relationships, and anticonvulsant activities of 2-amino-4H-pyrido[3,2-e][1,3]thiazin-4-one derivatives as orally active AMPA receptor antagonists.,  23  (8): [PMID:25792143] [10.1016/j.bmc.2015.02.033]

Source